ReviewFrontiers in molecular neuroscience2022
Role of Semaphorins in Ischemic Stroke.
Review in Frontiers in molecular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- FPR1 drives sepsis-associated cognitive impairment through region-specific transcriptional and splicing dysregulation in the brain.Metabolic brain disease · 2026Article
- Deciphering the disease ecosystem of ischemic stroke via multi-omics and prospects for therapeutic strategies.Frontiers in neuroscience · 2026Review
- Retinol-binding protein 4 in cardiovascular diseases: mechanisms and therapeutic perspectives.Frontiers in cardiovascular medicine · 2026Review
- Inflammatory Semaphorins in the Pathogenesis and Prognosis of Acute Ischemic Stroke.Medicina (Kaunas, Lithuania) · 2025Article
- scaLR: a low-resource deep neural network-based platform for single cell analysis and biomarker discovery.Briefings in bioinformatics · 2025Article
- The association of HIF1A gene polymorphism and its expression with ischemic stroke.Scientific reports · 2025Article
- Combined transcriptomic and proteomic analyses reveal relevant myelin features in mice with ischemic stroke.Functional & integrative genomics · 2025Article
- Article
- Transcription Factor EB: A Promising Therapeutic Target for Ischemic Stroke.Current neuropharmacology · 2024Article
- Neuroimmune mechanisms and therapies mediating post-ischaemic brain injury and repair.Nature reviews. Neuroscience · 2023Review
- An increase in Semaphorin 3A biases the axonal direction and induces an aberrant dendritic arborization in an in vitro model of human neural progenitor differentiation.Cell & bioscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke is one of the major causes of neurological morbidity and mortality in the world. Although the management of ischemic stroke has been improved significantly, it still imposes a huge burden on the health and property. The integrity of the neurovascular unit (NVU) is closely related with the prognosis of ischemic stroke. Growing evidence has shown that semaphorins, a family of axon guidance cues, play a pivotal role in multiple pathophysiological processes in NVU after ischemia, such as regulating the immune system, angiogenesis, and neuroprotection. Modulating the NVU function
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.